Premium
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA‐NCI roundtable symposium
Author(s) -
Landgren Ola,
Gormley Nicole,
Turley Danielle,
Owen Roger G.,
Rawstron Andy,
Paiva Bruno,
Barnett David,
Arroz Maria,
Wallace Paul,
Durie Brian,
Yuan Constance,
Dogan Ahmet,
StetlerStevenson Maryalice,
Marti Gerald E.
Publication year - 2014
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23831
Subject(s) - multiple myeloma , medicine , biomarker , surrogate endpoint , minimal residual disease , clinical endpoint , oncology , generalizability theory , intensive care medicine , clinical trial , drug development , drug , pharmacology , psychology , leukemia , developmental psychology , biochemistry , chemistry